Propanc Biopharma, Inc. Common Stock Market Cap ($4.63 Million)
Market Cap & Net Worth: Propanc Biopharma, Inc. Common Stock (PPCB)
Propanc Biopharma, Inc. Common Stock market cap. Propanc Biopharma, Inc. Common Stock (NASDAQ:PPCB) has a market capitalization of $4.63 Million ($4.63 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28679 globally and #5895 in its home market, demonstrating a 514.29% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Propanc Biopharma, Inc. Common Stock's stock price $1.72 by its total outstanding shares 9831116 (9.83 Million). Also see how efficiently does Propanc Biopharma, Inc. Common Stock generate cash for how efficiently the company converts equity into cash flow.
Propanc Biopharma, Inc. Common Stock Market Cap History (2026–2026)
Propanc Biopharma, Inc. Common Stock market cap history from 2026 to 2026. Data shows growth from $16.91 Million to $16.91 Million (0.00% CAGR). Check PPCB stock price and chart for real-time trading data and today's change.
Propanc Biopharma, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Propanc Biopharma, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Propanc Biopharma, Inc. Common Stock (PPCB) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PPCB by Market Capitalization
Companies near Propanc Biopharma, Inc. Common Stock in the global market cap rankings as of November 4, 2026. Also see PPCB total asset value for a full breakdown of the balance sheet.
Key companies related to Propanc Biopharma, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Propanc Biopharma, Inc. Common Stock (2026–2026)
Market capitalization of Propanc Biopharma, Inc. Common Stock from 2026 to today. Between 2026 and today, Propanc Biopharma, Inc. Common Stock's market cap moved from $16.91 Million to $ 16.91 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $16.91 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Propanc Biopharma, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.63 Million USD |
| MoneyControl | $4.63 Million USD |
| MarketWatch | $4.63 Million USD |
| marketcap.company | $4.63 Million USD |
| Reuters | $4.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. Th… Read more